Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Experts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.

EP: 1.The Evolution of Imaging Techniques in Prostate Cancer

EP: 2.The Utility of PSMA PET in Prostate Cancer

EP: 3.Clinical Development of PSMA-Targeted Therapies

EP: 4.Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP: 5.Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP: 6.Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP: 7.PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

EP: 8.LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP: 9.An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP: 10.SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP: 11.Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP: 12.Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

Now Viewing

EP: 13.Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Related Videos

Related Content

Advertisement

May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Related Content

Advertisement

May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.